Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbocromen
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carbocromen is a vasodilator used primarily for the treatment of cardiac ischemia, angina pectoris, and hypertension. It was marketed in Germany but has been discontinued due to the risk of arrhythmia development. The drug acts by dilating blood vessels, improving blood flow, particularly in coronary vessels. Its mechanism of action is not fully defined but involves vasodilation, which may be related to phosphodiesterase inhibition.
- Brand names
- ChromonarIntenkordinIntensainIntercordin
- Other names
- CarbochromenCarbochromeneCarbocromene
02
Targets
PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on Carbocromen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbocromen.